Author: De Jong, Cornelis N.; Saes, Lotte; Klerk, Clara P. W.; Van der Klift, Marjolein; Cornelissen, Jan J.; Broers, Annoek E. C.
Title: Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience Document date: 2017_10_26
ID: 1hcp36cw_24
Snippet: Median OS after initiation of second-line treatment with etanercept was 66 days (range 5-267) for the entire group. As shown in Fig 1, median OS was 99 days (range 47-267 days) for Causes of death were progressive aGVHD in 7 patients (47%), infection in 6 patients (40%), relapsed acute myeloid leukemia in one patient (6.7%), and cardiac arrest in 1 patient (6.7%). In half of the patients who succumbed to an infection, ongoing GVHD was considered .....
Document: Median OS after initiation of second-line treatment with etanercept was 66 days (range 5-267) for the entire group. As shown in Fig 1, median OS was 99 days (range 47-267 days) for Causes of death were progressive aGVHD in 7 patients (47%), infection in 6 patients (40%), relapsed acute myeloid leukemia in one patient (6.7%), and cardiac arrest in 1 patient (6.7%). In half of the patients who succumbed to an infection, ongoing GVHD was considered to be a contributing factor.
Search related documents:
Co phrase search for related documents- acute myeloid leukemia and second line: 1
- acute myeloid leukemia relapse and myeloid leukemia: 1, 2
- cardiac arrest and entire group: 1
- entire group and etanercept second line treatment: 1
- entire group and second line: 1
- entire group and second line treatment: 1
- etanercept second line treatment and second line: 1, 2, 3, 4, 5, 6, 7, 8
- etanercept second line treatment and second line treatment: 1, 2, 3, 4, 5, 6, 7, 8
- etanercept second line treatment initiation and second line: 1
- etanercept second line treatment initiation and second line treatment: 1
- myeloid leukemia and second line: 1, 2
- myeloid leukemia and second line treatment: 1
Co phrase search for related documents, hyperlinks ordered by date